The study is enrolling participants to see if the disitamab vedotin works to treat bladder cancer when used alone or when it is used in combination with pembrolizumab.

Do you have bladder cancer and have had your bladder removed? If so, you may be able to take part in a research study to determine if patients need additional treatment called immunotherapy to prevent cancer from coming back.

The purpose of this study is to combine standard radiation therapy with drugs that stimulate the body's immune system against cancer cells (by targeting the protein PD-1), while adding drugs which also target the pathway that the tumor uses to evade the immune system (the CD73 and A2a/b pathways).The main goal of this study is to find out if study treatment with zimberelimab (an antibody which binds the protein PD-1) and stereotactic body radiation therapy (SBRT) alone or in combination with quemliclustat (a drug which blocks CD73), with or without etrumadenant (a drug which blocks the A2a/b) given before surgery is safe and if it can further increase the immune response against the tumor.

Have you torn your ACL and undergone reconstruction surgery? Or do you have no history of lower extremity surgery? You may be eligible to participate in a research study to determine the effects of stroboscopic vision on walking gait biomechanics in those who have torn their ACL, and if somatosensory function may influence these changes.

This study is being done to answer the following questions: 1) Can the study drug iberdomide be given after idecabtagene vicleucel (ide-cel (Abecma)) CAR-T in multiple myeloma safely and with acceptably few and mild side effects? 2) For how long does multiple myeloma stay under control (in remission) if patients receive the study drug iberdomide after they have received ide-cel (Abecma) CAR-T? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your multiple myeloma. The usual approach is defined as care most people get for multiple myeloma.

This study aims to understand how a person's race and where they live affect the quality of breast cancer care they receive. We invite Black and/or African American breast cancer patients and survivors from specific areas of North Carolina to participate in a virtual focus group. The purpose of this focus group is to get your feedback about maps and other tools our team has created to show how breast cancer care quality varies around the state and by race. We also want to hear your experiences seeking care in your area, and your ideas about possible reasons behind the patterns in your area.

The purpose of the study is to compare the effects of glofitamab with combination of drugs. There will be two arms or groups. One group will receive glofitamab + Pola-R-CHP. The other group will receive only Pola-R-CHP. Pola-R-CHP includes: Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone

Test whether language adaptation effects can be seen in eye-movement analysis.

This study is seeking to enroll patients who have had previous gastric sleeve procedures to determine whether the current method of calculating stomach volume using ultrasound is accurate in this population. Compensation for your time will be provided.

What factors influence how the brain takes in sugar to use it as energy? If you are between the ages of 18-45 years old and are healthy and of normal weight, you might be eligible to participate in this study to help us understand how the way sugar enters the body affects how sugar enters the brain.